Status:
COMPLETED
Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder
Lead Sponsor:
Sumitomo Pharma America, Inc.
Conditions:
Insomnia
Generalized Anxiety Disorder
Eligibility:
All Genders
18-64 years
Phase:
PHASE4
Brief Summary
To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder. All subjects will receive an a...
Detailed Description
An 8-week, randomized, double-blind, placebo-controlled, parallel-group adjunctive therapy trial. The study consists of subjects with insomnia related to Generalized Anxiety Disorder who will be treat...
Eligibility Criteria
Inclusion
- Subjects, between the ages of 18 and 64 years inclusive
- Subjects with Generalized Anxiety Disorder (GAD)
- Subjects with insomnia related to GAD.
Exclusion
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2006
Estimated Enrollment :
420 Patients enrolled
Trial Details
Trial ID
NCT00235508
Start Date
June 1 2005
End Date
April 1 2006
Last Update
February 22 2012
Active Locations (64)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States
2
Mesa, Arizona, United States
3
Scottsdale, Arizona, United States
4
Irvine, California, United States